Here are the DEF 14A proxy statements from Harvard Bioscience Inc (HBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HBIO filings page.
Harvard Bioscience, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on June 2, 2026. Holders of 4,510,217 shares of common stock as of April 7, 2026 may participate and vote online.
Stockholders will elect two Class II directors (John Duke and Katherine A. Eade), ratify Grant Thornton LLP as auditor for 2026, cast an advisory vote on executive pay, and consider amendments to increase the Employee Stock Purchase Plan by 120,000 shares and the 2021 Incentive Plan by 400,000 shares of common stock. The board recommends voting FOR all proposals and highlights its independent committee structure, ESG initiatives, clawback and insider trading policies, and detailed director and executive compensation programs.
Harvard Bioscience is asking stockholders to approve a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-15, plus authority to adjourn the special meeting if more votes are needed. The goal is to help the company regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving deficiency notices and a compliance deadline of March 30, 2026.
The special meeting will be held virtually on March 6, 2026, and holders of common stock as of January 21, 2026 can vote. As of December 31, 2025, there were 44,719,894 shares of common stock outstanding, and the board recommends voting in favor of both proposals.